A detailed history of Charles Schwab Investment Management Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,295,837 shares of PCVX stock, worth $119 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,295,837
Previous 876,237 47.89%
Holding current value
$119 Million
Previous $66.2 Million 123.6%
% of portfolio
0.03%
Previous 0.01%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$70.52 - $117.12 $29.6 Million - $49.1 Million
419,600 Added 47.89%
1,295,837 $148 Million
Q2 2024

Aug 12, 2024

BUY
$60.06 - $78.77 $2.56 Million - $3.36 Million
42,619 Added 5.11%
876,237 $66.2 Million
Q1 2024

May 08, 2024

BUY
$59.79 - $81.05 $6.17 Million - $8.36 Million
103,180 Added 14.13%
833,618 $56.9 Million
Q4 2023

Feb 06, 2024

BUY
$45.35 - $63.41 $796,799 - $1.11 Million
17,570 Added 2.46%
730,438 $45.9 Million
Q3 2023

Nov 08, 2023

BUY
$46.0 - $53.1 $4.8 Million - $5.54 Million
104,398 Added 17.16%
712,868 $36.3 Million
Q2 2023

Aug 09, 2023

BUY
$34.66 - $54.07 $4.19 Million - $6.53 Million
120,837 Added 24.78%
608,470 $30.4 Million
Q1 2023

May 11, 2023

SELL
$36.27 - $47.2 $30,684 - $39,931
-846 Reduced 0.17%
487,633 $18.3 Million
Q4 2022

Feb 13, 2023

BUY
$20.58 - $47.95 $2.95 Million - $6.87 Million
143,253 Added 41.5%
488,479 $23.4 Million
Q3 2022

Nov 14, 2022

BUY
$21.69 - $28.53 $1.21 Million - $1.59 Million
55,579 Added 19.19%
345,226 $8.29 Million
Q2 2022

Aug 15, 2022

BUY
$17.68 - $26.58 $483,654 - $727,122
27,356 Added 10.43%
289,647 $6.3 Million
Q1 2022

May 13, 2022

BUY
$17.46 - $26.36 $348,711 - $526,461
19,972 Added 8.24%
262,291 $6.34 Million
Q4 2021

Feb 11, 2022

BUY
$19.32 - $26.45 $88,311 - $120,902
4,571 Added 1.92%
242,319 $5.77 Million
Q3 2021

Nov 16, 2021

BUY
$20.26 - $26.97 $1.32 Million - $1.76 Million
65,145 Added 37.74%
237,748 $6.03 Million
Q2 2021

Aug 16, 2021

BUY
$16.45 - $24.06 $599,191 - $876,385
36,425 Added 26.75%
172,603 $3.89 Million
Q1 2021

May 17, 2021

BUY
$18.66 - $29.16 $346,796 - $541,938
18,585 Added 15.8%
136,178 $2.69 Million
Q4 2020

Feb 16, 2021

BUY
$26.57 - $51.74 $40,598 - $79,058
1,528 Added 1.32%
117,593 $3.13 Million
Q3 2020

Nov 13, 2020

BUY
$26.5 - $55.4 $3.08 Million - $6.43 Million
116,065 New
116,065 $5.73 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.43B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.